Immunotherapy for Brain Cancer, with David Reardon

On April 24, 2014, David A. Reardon, M.D., clinical director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute, discussed current immunotherapy treatment options for patients with brain cancer, and how close we are to making these treatments available to more patients.
Cancer Research Institute's Breakthroughs in Cancer Immunotherapy Webinar Series are offered free to the public and feature informative updates from leaders in cancer immunotherapy, followed by a moderated Q&A. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.

[@kokkie1953]

I am very happy to tell you our daughter who was dx in Jan.2006 with GBM is doing well and has just passed her 8.5 year of survival after been given a grim prognosis of 3/9 months...she has been med free for many years .Thank you for your wonderful video

[@davefay660]

Hi Femme -- that's wonderful news! I hope things are still well for your daughter. Did you use any new therapies?

[@BisMaxx]

Femme Hensen curious as well

[@occamsrazor1474]

Although I suspect it's rare, my immune system instantly recognised a small cluster of emergent Glioblastoma cells in my right temporal lobe .
The threat was contained within a small cerebral abscess , thus preventing tumour formation or any infiltration beyond the abscess boundary.
Due to immuno memory , it is hypothesised that I am now naturally inoculated against GBM4.
The biopsy of the hardened abscess case showed some biomarkers for this cancer.
All MRIs over the last 1.5 years have shown now evidence of disease.
I have always been asymptomatic .